Aurobindo Pharma | USFDA Approval – Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate Monohydrate Nasal Spray, which is equivalent to Nasonex Nasal Spray. – This new product will be launched in the first quarter of fiscal year 2025, potentially opening up new revenue streams for the company

Posted on by earn

Aurobindo Pharma | USFDA Approval

– Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate Monohydrate Nasal Spray, which is equivalent to Nasonex Nasal Spray.
– This new product will be launched in the first quarter of fiscal year 2025, potentially opening up new revenue streams for the company

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Please follow and like us:
fb-share-icon
Tweet
Pin Share

Related Posts

Stocks With Major Volume and News MUTUAL FUND SIP MONEY TRIPPLE IN 10 YEARS FII DATA 18 SEPTEMBER MIDCAP AND SMALL CAP SHARES SELL MARKET LIVE
Click here to apply for a business loan. For many hunters, the ultimate goal is to track down and harvest a trophy buck. You can also request that we erase any personal data we hold about you.